arrow
M

Mary T. Obermeier

Bristol-Myers Squibb
H指数:19
被引数:2,026

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Enhancing the Oral Bioavailability of a Poorly Soluble Pan-CK2 Kinase Inhibitor: Leveraging a Phosphate Prodrug Strategy to Overcome Dissolution-Limited Absorption and Improve Systemic Exposure during Dose Escalation
2026-01-010
PRE
Azatricyclic Inverse Agonists of RORγt That Demonstrate Efficacy in Models of Rheumatoid Arthritis and Psoriasis
2021-04-306
OA
Tricyclic-Carbocyclic RORγt Inverse Agonists-Discovery of BMS-986313
2021-02-1612
PREAI
Novel Tricyclic Pyroglutamide Derivatives as Potent RORγt Inverse Agonists Identified using a Virtual Screening Approach
2020-11-0617
OAAI
Driving Potency with Rotationally Stable Atropisomers: Discovery of Pyridopyrimidinedione-Carbazole Inhibitors of BTK
2020-09-165
OAAI
Discovery of BMS-986251: A Clinically Viable, Potent, and Selective RORγt Inverse Agonist
2020-03-3137
OAAI
Rationally Designed, Conformationally Constrained Inverse Agonists of RORγt-Identification of a Potent, Selective Series with Biologic-Like in Vivo Efficacy
2019-10-2233
PREAI
Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK)
2019-03-2086
OAAI
Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase δ (P13Kδ) Inhibitor for the Treatment of Immunological Disorders
2017-06-0517
PREAI
Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers
2016-09-19117
PREAI
Small Molecule Reversible Inhibitors of Bruton's Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177)
2016-08-2655
PREAI
Discovery of the Selective CYP17A1 Lyase Inhibitor BMS-351 for the Treatment of Prostate Cancer

用于治疗前列腺癌的选择性CYP17A1裂解酶抑制剂BMS-351的发现

2015-12-147
OAAI
Anti-tumor activity of BMS-595, a novel CK2 kinase inhibitor
2015-08-011
PRE
The identification of BMS-595, an orally active imidazo[1,2-b]pyridazine CK2 inhibitor with in vivo anti-tumor activity
2015-08-010
PRE
Phase I Dose-Escalation Study of the Novel Antiandrogen BMS-641988 in Patients with Castration-Resistant Prostate Cancer
2011-02-1535
OAAI
Androgen receptor antagonists: Lead optimization and preclinical pharmacology
2010-04-010
PRE
Discovery of dapagliflozin: A potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
2008-02-09619
PREAI